icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
x8sHcmhrnMLTSe8t